Phase I Study of TAS-102 Administered to Japanese Patients with Advanced Solid Tumors

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221506

Enrollment

Registered

2011-07-06

Start date

2011-07-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with solid tumors

Interventions

investigational material(s) Generic name etc : TAS-102 INN of investigational material : Therapeutic category code : 422 Antimetabolic agents Dosage and Administration for Investigational material :

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Signed, written informed consent. - Histologically or cytologically confirmed solid tumor. - Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.

Exclusion criteria

Exclusion criteria: - Patient who has serious concomitant disease

Design outcomes

Primary

Measure	Time frame
Safety CTCAE (ver.3.0)	—

Secondary

Measure	Time frame
Pharmacokinetics,Efficacy RECIST (ver.1.0)	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026